Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...

The team led by Dr. May Faraj, Professor of Nutrition at Université de Montréal and Director of the Nutrition, Lipoproteins ...